APLICACIÓN CÉLULAS MADRE

NEW YORK, Aug. 14, 2013 /PRNewswire/ -- The Tisch MS Research Center of New York announced today that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) to commence a Phase 1 trial using autologous neural stem cells in the treatment of multiple sclerosis (MS). MS is a chronic human autoimmune disease of the central nervous system that leads to myelin damage and neurodegeneration and affects approximately 2.1 million people worldwide.

La FDA aprueba el primer estudio en USA con celulas madres en el tratamiento de la Esclerosis Multiple